Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Cash & Current Investments (2020 - 2025)

Terns Pharmaceuticals filings provide 6 years of Cash & Current Investments readings, the most recent being $995.0 million for Q4 2025.

  • Quarterly Cash & Current Investments rose 177.81% to $995.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $995.0 million through Dec 2025, up 177.81% year-over-year, with the annual reading at $995.0 million for FY2025, 177.81% up from the prior year.
  • Cash & Current Investments hit $995.0 million in Q4 2025 for Terns Pharmaceuticals, up from $271.5 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $995.0 million in Q4 2025 and bottomed at $139.8 million in Q2 2022.
  • Average Cash & Current Investments over 5 years is $271.3 million, with a median of $245.8 million recorded in 2024.
  • The largest annual shift saw Cash & Current Investments surged 1572.2% in 2021 before it fell 24.46% in 2022.
  • Terns Pharmaceuticals' Cash & Current Investments stood at $166.0 million in 2021, then dropped by 1.85% to $162.9 million in 2022, then skyrocketed by 61.71% to $263.4 million in 2023, then surged by 35.96% to $358.2 million in 2024, then skyrocketed by 177.81% to $995.0 million in 2025.
  • Per Business Quant, the three most recent readings for TERN's Cash & Current Investments are $995.0 million (Q4 2025), $271.5 million (Q3 2025), and $315.4 million (Q2 2025).